Rosemont Celebrates One Year Of Independence With 49% Growth
Private Equity Inflexion Acquired Business From Perrigo
A year on from being spun-out of Perrigo and acquired by private equity, liquid generics specialist Rosemont Pharmaceuticals has revealed new details of the UK-based firm’s operations.
You may also be interested in...
Juno Deal Gives Rosemont Access To Canada
Juno Pharmaceuticals has struck a deal that will see it act as the exclusive distributor for UK-based Rosemont’s oral liquid medicines in Canada.
Perrigo Completes $1.5bn Rx Divestment
Perrigo has completed the divestment of its Rx prescription generics business to Altaris Capital Partners for $1.55bn, completing its transition to become a self-care consumer healthcare-focused company. Altaris has rebranded the unit as Padagis.
Vectura Agrees £958m Takeover Following Hikma Advair Launch
Weeks after partner Hikma launched its generic version of GSK’s Advair, Wiltshire-based Vectura has agreed a takeover offer by private equity Carlyle, which aims to build a market leading inhalation specialist CDMO.